Neurology

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed important considerations for genetic counselors thinking about using AI tools in their practice.

Recapping some the FDA approvals and regulatory updates in cell and gene therapy that made waves in 2025.

Review top news and interview highlights from the week ending December 19, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending December 12, 2025.

Sharon Hesterlee, PhD, the president and CEO of the Muscular Dystrophy Association, discussed the upcoming conference and the evolving therapeutic landscape in neuromuscular disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending December 5, 2025.

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed a session she chaired at the NSGC Annual Conference.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending November 28, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA also added a new Warnings & Precaution for heightened susceptibility to serious infections caused by immunosuppression.

According to Novartis, it is the first gene replacement therapy to have been approved “for this broad population.”

Review top news and interview highlights from the week ending November 21, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

According to Intellia, the FDA placed clinical holds on both MAGNITUDE and MAGNITUDE-2 on October 29, 2025.

Review top news and interview highlights from the week ending November 7, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Naji Gehchan, MD, MBA, the chief medical and development officer of Kyverna Therapeutics, went over new data the company presented at AANEM’s 2025 meeting.

uniQure pointed out that this new feedback stands in contrast to its previous communications with the FDA in several Type B meetings.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.